NewAmsterdam Pharma to present obicetrapib Alzheimer's data at AAIC 2026
NewAmsterdam Pharma will present four analyses at the Alzheimer's Association International Conference (AAIC) 2026 in London from 12 to 15 July, exploring whether its oral CETP inhibitor obicetrapib could have a role in preventing early Alzheimer's disease, well beyond its primary cardiovascular indication.
The presentations draw on sub-analyses of the BROADWAY Phase 3 trial, which was originally designed to evaluate LDL-C reductions in patients with atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolaemia. A pre-specified biomarker analysis within that study tracked plasma markers of Alzheimer's pathology over 12 months in 1,535 patients, including 367 carriers of the ApoE4 allele, the best-established genetic risk factor for late-onset Alzheimer's disease.
What the data show
NewAmsterdam reported statistically significant reductions in absolute change in p-tau217 compared to placebo over 12 months, both in the full analysis set (p=0.025; n=1,535) and in ApoE4 carriers specifically (p=0.022; n=367). P-tau217 is widely regarded as one of the most sensitive plasma biomarkers for early Alzheimer's pathology, and its trajectory has been used as a surrogate endpoint in several prevention trials. The company also reported favourable trends across secondary biomarkers including neurofilament light chain (NFL), GFAP, p-tau181 and the amyloid beta 42/40 ratio.
An important caveat is that the analysis was not randomised specifically for Alzheimer's endpoints and was not controlled for baseline differences between the treatment and placebo populations, though the statistical models were adjusted for baseline biomarker values and age. The company has been careful to present these as hypothesis-generating, positioning them as the basis for a potential dedicated prevention trial rather than evidence of efficacy in Alzheimer's disease.
A third oral presentation will examine whether ApoE4 carrier status predicts differential dose response to CETP inhibition, a finding that could inform enrichment strategies in future Alzheimer's prevention trials. A fourth presentation focuses on the multi-pathway mechanisms by which CETP inhibition may affect lipid-mediated Alzheimer's pathophysiology.
Market context and competitive landscape
The Alzheimer's prevention space has attracted substantial industry interest following the commercial launches of lecanemab and donanemab, both anti-amyloid antibodies administered intravenously. An oral, once-daily small-molecule approach would represent a meaningfully different commercial profile should obicetrapib demonstrate efficacy in a dedicated trial. NewAmsterdam's primary asset remains the ongoing PREVAIL cardiovascular outcomes trial, which enrolled over 9,500 patients and completed enrolment in April 2024; that readout is the principal near-term catalyst for the stock.
Several other CETP inhibitor programmes, including earlier-generation compounds from large-cap competitors, failed on cardiovascular outcomes, lending significance to NewAmsterdam's approach of using lower doses. The Alzheimer's angle differentiates obicetrapib further, though investors and clinicians will rightly treat the BROADWAY sub-analysis as exploratory until a prospectively designed, adequately powered prevention trial reports. European commercialisation rights for obicetrapib have already been exclusively licensed to the Menarini Group, giving NewAmsterdam a regional partner as it advances both indications.
The AAIC presentations are scheduled for 13 to 15 July at the ICC in London. The company has not announced a timeline for initiating a dedicated Alzheimer's prevention programme, and forward-looking clinical plans will likely depend on the reception these data receive from the scientific and regulatory community.